Patient and treatment heterogeneity were characterized within a sample of nonadherent buprenorphine members; an improved understanding of these factors may optimize patient—treatment matching and intervention efforts.
Vijay R. Nadipelli, MS, BPharm
Advertisement
Articles by Vijay R. Nadipelli, MS, BPharm
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
Health Care Is Fixable: Workers’ Compensation Shows Employers Don’t Need to Wait for Washington
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5